Lecanemab approval in EU: what should we be ready for?- the EANM perspective.
作者信息
Yakushev Igor, Verger Antoine, Brendel Matthias, Cecchin Diego, Fernandez Pablo Aguiar, Fraioli Francesco, Grimmer Timo, Tolboom Nelleke, Traub-Weidinger Tatjana, Guedj Eric, Van Weehaeghe Donatienne
机构信息
Department of Nuclear Medicine, School of Medicine, TUM University Hospital, Technical University of Munich, Klinikum rechts der Isar Ismaninger Str. 22, 81675, Munich, Germany.
Department of Nuclear Medicine and Nancyclotep Imaging Platform, CHRU Nancy, Université de Lorraine, Nancy, France.
出版信息
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1607-1610. doi: 10.1007/s00259-025-07066-9.
Abstract
摘要
相似文献
1
Lecanemab approval in EU: what should we be ready for?- the EANM perspective.欧盟批准lecanemab：我们应做好哪些准备？——欧洲核医学协会的观点
Eur J Nucl Med Mol Imaging. 2025 Apr;52(5):1607-1610. doi: 10.1007/s00259-025-07066-9.
2
FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective.美国食品药品监督管理局批准仑卡奈单抗：淀粉样蛋白正电子发射断层扫描广泛应用的真正开端？——欧洲核医学与分子影像学会神经影像学委员会观点
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1553-1555. doi: 10.1007/s00259-023-06177-5.
3
Lecanemab: First Approval.莱卡奈单抗：首次获批。
Drugs. 2023 Mar;83(4):359-365. doi: 10.1007/s40265-023-01851-2.
4
Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective.抗淀粉样蛋白单克隆抗体（mAb）药物乐卡奈单抗用于早期阿尔茨海默病的安全性和有效性：药物警戒视角
Br J Clin Pharmacol. 2025 May;91(5):1352-1360. doi: 10.1002/bcp.70021. Epub 2025 Mar 6.
5
Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease.利斯的明透皮贴剂（Leqembi）并不适合阿尔茨海默病患者。
Adv Clin Exp Med. 2023 Sep;32(9):943-947. doi: 10.17219/acem/171379.
6
Predicting the Societal Value of Lecanemab in Early Alzheimer's Disease in Japan: A Patient-Level Simulation.预测日本早期阿尔茨海默病中lecanemab的社会价值：一项患者层面的模拟研究
Neurol Ther. 2023 Aug;12(4):1133-1157. doi: 10.1007/s40120-023-00492-7. Epub 2023 May 15.
7
Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?仑卡奈单抗获批用于阿尔茨海默病患者治疗的影响：是增量步骤还是范式转变？
Neurology. 2023 Oct 3;101(14):610-620. doi: 10.1212/WNL.0000000000207438. Epub 2023 Jun 9.
8
The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint.用于治疗阿尔茨海默病的淀粉样蛋白靶向疗法——lecanemab的可负担性：欧洲阿尔茨海默病临床医生俱乐部（EADC）和欧洲临床药理学会（EC）的观点
Lancet Reg Health Eur. 2023 May 22;29:100657. doi: 10.1016/j.lanepe.2023.100657. eCollection 2023 Jun.
9
Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis.用lecanemab进行单克隆治疗轻度阿尔茨海默病：一项系统评价和荟萃分析。
Ageing Res Rev. 2025 Feb;104:102620. doi: 10.1016/j.arr.2024.102620. Epub 2024 Dec 3.
10
Lecanemab: Appropriate Use Recommendations.仑卡奈单抗：合理使用建议。
J Prev Alzheimers Dis. 2023;10(3):362-377. doi: 10.14283/jpad.2023.30.
引用本文的文献
1
The Status of Neuroimaging with SPECT and PET in Germany: Results from the 1st Survey on Nuclear Neuroimaging in Germany in 2023.德国单光子发射计算机断层扫描和正电子发射断层扫描神经成像的现状：2023年德国首次核神经成像调查结果
Nuklearmedizin. 2025 Apr 15. doi: 10.1055/a-2566-1487.
2
Capacity for brain amyloid PET in Germany: Results from the 1st survey on nuclear brain imaging in Germany.德国脑淀粉样蛋白PET的能力：德国首次核脑成像调查结果
Eur J Nucl Med Mol Imaging. 2025 Mar 27. doi: 10.1007/s00259-025-07237-8.
本文引用的文献
1
Aβ status assessment in a hypothetical scenario prior to treatment with disease-modifying therapies: Evidence from 10-year real-world experience at university memory clinics.在使用疾病修饰疗法治疗前的假设情景中的淀粉样蛋白β状态评估：来自大学记忆诊所10年真实世界经验的证据。
Alzheimers Dement (Amst). 2024 Nov 22;16(4):e70031. doi: 10.1002/dad2.70031. eCollection 2024 Oct-Dec.
2
Stress testing the Centiloid: Precision and variability of PET quantification of amyloid pathology.用 Centiloid 进行压力测试：淀粉样蛋白病理 PET 定量的精度和可变性。
Alzheimers Dement. 2024 Aug;20(8):5102-5113. doi: 10.1002/alz.13883. Epub 2024 Jul 4.
3
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准：阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
4
Impact of PET Reconstruction on Amyloid-β Quantitation in Cross-Sectional and Longitudinal Analyses.正电子发射断层扫描（PET）重建对横断面和纵向分析中淀粉样蛋白-β定量的影响。
J Nucl Med. 2024 May 1;65(5):781-787. doi: 10.2967/jnumed.123.266188.
5
Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests.阿尔茨海默病的高精度血液检测在准确性上可与临床脑脊液检测相媲美或优于后者。
Nat Med. 2024 Apr;30(4):1085-1095. doi: 10.1038/s41591-024-02869-z. Epub 2024 Feb 21.
6
European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders.基于生物标志物的神经认知障碍诊断的欧洲协会间推荐意见。
Lancet Neurol. 2024 Mar;23(3):302-312. doi: 10.1016/S1474-4422(23)00447-7.
7
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
8
Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease.用于阿尔茨海默病的淀粉样蛋白靶向单克隆抗体
JAMA. 2023 Aug 8;330(6):507-509. doi: 10.1001/jama.2023.11703.
9
Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape.用于阿尔茨海默病的基于血液的生物标志物：在变革的全球医疗保健环境中的当前状态和未来用途。
Neuron. 2023 Sep 20;111(18):2781-2799. doi: 10.1016/j.neuron.2023.05.017. Epub 2023 Jun 8.
10
FDA approval of lecanemab: the real start of widespread amyloid PET use? - the EANM Neuroimaging Committee perspective.美国食品药品监督管理局批准仑卡奈单抗：淀粉样蛋白正电子发射断层扫描广泛应用的真正开端？——欧洲核医学与分子影像学会神经影像学委员会观点
Eur J Nucl Med Mol Imaging. 2023 May;50(6):1553-1555. doi: 10.1007/s00259-023-06177-5.
Zotero 插件